A detailed history of Ubs Asset Management Americas Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 266,756 shares of CYTK stock, worth $13.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
266,756
Previous 251,942 5.88%
Holding current value
$13.9 Million
Previous $13.7 Million 3.18%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$51.22 - $60.16 $758,773 - $891,210
14,814 Added 5.88%
266,756 $14.1 Million
Q2 2024

Aug 13, 2024

BUY
$47.86 - $75.05 $6.41 Million - $10.1 Million
134,020 Added 113.65%
251,942 $13.7 Million
Q1 2024

May 15, 2024

BUY
$63.75 - $108.06 $86,508 - $146,637
1,357 Added 1.16%
117,922 $8.27 Million
Q4 2023

Feb 14, 2024

SELL
$26.88 - $83.49 $115,019 - $357,253
-4,279 Reduced 3.54%
116,565 $9.73 Million
Q3 2023

Nov 13, 2023

BUY
$29.46 - $36.61 $156,079 - $193,959
5,298 Added 4.59%
120,844 $3.56 Million
Q1 2023

May 15, 2023

BUY
$33.36 - $45.71 $608,953 - $834,390
18,254 Added 18.76%
115,546 $4.07 Million
Q4 2022

Feb 14, 2023

BUY
$35.77 - $51.11 $554,900 - $792,869
15,513 Added 18.97%
97,292 $4.46 Million
Q3 2022

Nov 14, 2022

SELL
$38.54 - $54.52 $681,040 - $963,422
-17,671 Reduced 17.77%
81,779 $3.96 Million
Q2 2022

Aug 12, 2022

BUY
$33.93 - $48.92 $197,031 - $284,078
5,807 Added 6.2%
99,450 $3.91 Million
Q1 2022

May 16, 2022

SELL
$29.74 - $46.0 $15,613 - $24,150
-525 Reduced 0.56%
93,643 $3.45 Million
Q4 2021

Feb 14, 2022

BUY
$34.35 - $46.38 $850,437 - $1.15 Million
24,758 Added 35.67%
94,168 $4.29 Million
Q3 2021

Nov 15, 2021

BUY
$18.54 - $35.74 $120,046 - $231,416
6,475 Added 10.29%
69,410 $2.48 Million
Q2 2021

Aug 16, 2021

SELL
$19.79 - $26.99 $9,538 - $13,009
-482 Reduced 0.76%
62,935 $1.25 Million
Q1 2021

May 14, 2021

BUY
$18.57 - $25.68 $182,765 - $252,742
9,842 Added 18.37%
63,417 $1.48 Million
Q4 2020

Mar 01, 2021

BUY
$15.26 - $28.61 $9,873 - $18,510
647 Added 1.22%
53,575 $1.11 Million
Q3 2020

Nov 13, 2020

BUY
$20.58 - $28.96 $93,001 - $130,870
4,519 Added 9.34%
52,928 $1.15 Million
Q2 2020

Aug 14, 2020

SELL
$11.15 - $24.64 $122,114 - $269,857
-10,952 Reduced 18.45%
48,409 $1.14 Million
Q1 2020

May 15, 2020

BUY
$8.75 - $16.3 $110,950 - $206,684
12,680 Added 27.16%
59,361 $699,000
Q4 2019

Feb 14, 2020

SELL
$7.95 - $11.84 $89,763 - $133,685
-11,291 Reduced 19.48%
46,681 $495,000
Q3 2019

Nov 14, 2019

BUY
$10.82 - $14.25 $313,217 - $412,509
28,948 Added 99.74%
57,972 $659,000
Q1 2019

May 14, 2019

BUY
$5.95 - $10.19 $16,802 - $28,776
2,824 Added 10.78%
29,024 $0
Q2 2018

Aug 14, 2018

BUY
$6.9 - $9.9 $180,780 - $259,380
26,200 New
26,200 $0

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.92B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.